ZA200604880B - Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip - Google Patents
Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip Download PDFInfo
- Publication number
- ZA200604880B ZA200604880B ZA200604880A ZA200604880A ZA200604880B ZA 200604880 B ZA200604880 B ZA 200604880B ZA 200604880 A ZA200604880 A ZA 200604880A ZA 200604880 A ZA200604880 A ZA 200604880A ZA 200604880 B ZA200604880 B ZA 200604880B
- Authority
- ZA
- South Africa
- Prior art keywords
- hip joint
- approximately
- cartilage
- patient
- application
- Prior art date
Links
- 101000911772 Homo sapiens Hsc70-interacting protein Proteins 0.000 title claims description 24
- 201000008482 osteoarthritis Diseases 0.000 title claims description 18
- 230000007547 defect Effects 0.000 title claims description 13
- 238000000034 method Methods 0.000 title description 15
- 230000006378 damage Effects 0.000 title description 9
- 208000015100 cartilage disease Diseases 0.000 title description 6
- 210000004394 hip joint Anatomy 0.000 claims description 45
- 230000005684 electric field Effects 0.000 claims description 36
- 210000000845 cartilage Anatomy 0.000 claims description 33
- 210000001519 tissue Anatomy 0.000 claims description 28
- 230000008878 coupling Effects 0.000 claims description 10
- 238000010168 coupling process Methods 0.000 claims description 10
- 238000005859 coupling reaction Methods 0.000 claims description 10
- 208000014674 injury Diseases 0.000 claims description 10
- 210000001188 articular cartilage Anatomy 0.000 claims description 9
- 230000005672 electromagnetic field Effects 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- 210000001258 synovial membrane Anatomy 0.000 claims description 4
- 210000004872 soft tissue Anatomy 0.000 claims description 3
- 208000025978 Athletic injury Diseases 0.000 claims description 2
- 230000008733 trauma Effects 0.000 claims description 2
- 206010041738 Sports injury Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 description 22
- 210000003205 muscle Anatomy 0.000 description 17
- 210000001624 hip Anatomy 0.000 description 14
- 210000000588 acetabulum Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000906034 Orthops Species 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000011160 research Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000002449 bone cell Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000000629 knee joint Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000016284 Aggrecans Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000030016 Avascular necrosis Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241001441571 Hiodontidae Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010031264 Osteonecrosis Diseases 0.000 description 1
- 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000617 arm Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001827 electrotherapy Methods 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 108010017843 platelet-derived growth factor A Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000000513 rotator cuff Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- -1 sulfation Polymers 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Landscapes
- Prostheses (AREA)
Description
METHOD AND DEVICE FOR TREATING OSTEOARTHRIT IS AND CARTILAGE
DISEASE, DEFECTS, AND INJURIES IN THE HUMAN HIP
[0001] The present patent application claims priority to U.S. Provisional Patent
Application Nos. 60/520,088 filed November 14, 2003 and 60/535,734 filed January 9, 2004.
The present patent application also claims priority to U.S. Patent Application Serial No. 10/257,126, filed October 8, 2002, entitled “Regulation of Genes Via Application of Specific and Selective Electrical and Electromagnetic Signals”, which claims priority to
PCT/US01/05991 filed February 23, 2001, and U.S. Provisional Application No. 60/184,491 filed February 23, 2000, and U.S. Patent Application Serial Nos. 10/255,241, filed September 26, 2002, entitled “Regulation of Aggrecan Gene Expression with a Specific and Selective
Electrical Signal”, 10/267,708, filed October 9, 2002, entitled “Regulation of Type II Collagen
Gene Expression with a Specific and Selective Electrical Signal”, 10/457,167, filed June 9, 2003, entitled “Method and Apparatus for Treating Osteoarthritis, Cartilage Disease, Defects and
Injuries in the Human Knee Joint,” 10/461,188, filed June 13, 2003, entitled “Regulation of
Matrix Metalloproteinase Gene Expression Using Specific and Selective Electrical and
Electromagnetic Signals,” and 10/603,226, filed June 25, 2003, entitled “Portable Electrotherapy
Device for Treating Osteoarthritis and Other Diseases, Defects and Injuries of the Knee Joint.”
The contents of all of these applications are hereby incorporated by reference in their entireties.
[0002] The present invention is directed to a method of determining the voltage and current output required for the application of specific and selective electric and electromagnetic signals to diseased articular tartilags in the treatment of osteoarthritis, cartilage defects due to trauma or sports injuries, or as an adjunct with other therapies (e.g., cell transplantation, tissue- engineered scaffolds, growth factors, etc.) for treating cartilage defects in the human hip joint and a device for delivering such signals to a patient’s hip.
[0003] The bioelectrical interactions and activity believed to be present in a variety of biological tissues and cells are one of the least understood of the physiological processes.
However, there has recently been much research into these interactions and activities related to the growth and repair of certain tissues and cells. In particular, there has been considerable interest in stimulation by electric and electromagnetic fields and their effect on the growth and repair of bene and cartilage. Scientists believe that such research might be useful in the development of new treatments for a variety of medical problems.
[0004] Osteoarthritis, also known as degenerative joint disease, is characterized by degeneration of articular cartilage as well as proliferation and remodeling of subchondral bone.
The usual symptoms are stiffness, limitation of motion, and pain. Osteoarthritis is the most common form of arthritis, and prevalence rates increase markedly with age. It has been shown that elderly patients with self-reported osteoarthritis visit doctors twice as frequently as their unaffected peers. Such patients also experience more days of restricted activity and bed confinement compared to others in their age group. In one study, the majority of symptomatic patients became significantly disabled during an 8-year follow-up period (Massardo et al., Ann
Rheum Dis 48:893-897, 1989). ’
[0005] Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the primary treatment modality for osteoarthritis. It is unknown whether the efficacy of NSAIDs is dependent upon their analgesic or anti-inflammatory properties or the slowing of degenerative processes in the cartilage. There is also a concern that NSAIDs may be deleterious to patients. For example,
NSAIDs display well-known toxic effects in the stomach, gastrointestinal tract, liver and kidney.
Moreover, aspirin inhibits proteoglycan synthesis and normal cartilaginous repair processes in animals. One study in humans also suggested that indomethacin might accelerate breakdown of hip cartilage. All adverse effects appear more commonly in the elderly—the very population rnost susceptible to osteoarthritis.
[6006] In the disease commonly known as osteoporosis, bone demineralizes and becomes abnormelly rarefied. Bone comprises an organic component of cells and matrix as well as an inorganic or mineral component. The cells and matrix comprise a framework of collagenous fibers that is impregnated with the mineral component of calcium phosphate (85%) and calcium carbonate (10%) that imparts rigidity to bone. While osteoporosis is generally thought to afflict the elderly, certain types of osteoporosis may affect persons of all ages whose bones are not subject to functional stress. In such cases, patients may experience a significant loss of cortical and cancellous bone during prolonged periods of immobilization. Elderly patients are known to experience bone loss due to disuse when immobilized after fracture of a bone; this may ultimately lead to a secondary fracture in an already osteoporotic skeleton. Diminished bone density may lead to collapse of vertebrae, fractures of hips, lower arms, wrists and ankles, as well as incapacitating pains. Alternative non-surgical therapies for such diseases are needed.
[0007] Pulsed electromagnetic fields (PEMFs) and capacitive coupling (CC) have been used widely to treat non-healing fractures and related problems in bone healing since approval by the Food and Drug Administration in 1979. The original basis for the trial of this form of therapy was the observation that physical stress on bone causes the appearance of tiny electric currents that, along with mechanical strain, were thought to be the mechanisms underlying transduction of the physical stress into a signal that promotes bone formation. Along with direct electric field stimulation that was successful in the treatment of nonunion bone fractures, noninvasive technologies using PEMF and CC (where the electrodes are placed on the skin in the treatment zone) were also found to be effective. PEMFs generate small, induced currents (Faraday currents) in the highly conductive extracellular fluid, while CC directly causes currents in the tissues; both PEMFs and CC thereby mimic endogenous electrical currents.
[0008] The endogenous electrical currents, originally thought to be due to phenomena occurring at the surface of crystals in the bone, have been shown to be due primarily to movement of fluid containing electrolytes in channels of the bone containing organic constituents with fixed negative charges, generating what are called “streaming potentials.”
Studies of electrical phenomena in cartilage have demonstrated a mechanical-electrical transduction mechanism that resembles those described in bone, appearing when cartilage is mechanically compressed, causing movement of fluid and electrolytes over the surface of fixed negative charges in the proteoglycans and collagen in the cartilage matrix. These streaming potentials apparently serve a purpose in cartilage similar to that in bone, and, along with mechanical strain, lead to signal transduction that is capable of stimulating chondrocyte synthesis of matrix components. {6009} The main application of direct current, CC, and PEMTFs has been in orthopaedics in the healing of nonunion bone fractures (Brighton et al. J Bone Joint Surg 1981;63:2-13;
Brighton and Pollack J Bone Joint Surg 1985;67:577-585; Bassett et al. Crit Rev Biomed Eng 1989;17:451-529; Bassett et al. J Am Med Assoc 1982;247:623-628). Clinical responses have been reported in avascular necrosis of hips in adults and Legg-Perthe’s disease in children (Bassett et al. Clin Orthop 1989;246:172-176; Aaron et al. Clin Orthop 1989;249:209-218;
Harrison et al. J Pediatr Orthop 1984;4:579-584, 1984). It has also been shown that PEMFs (Mooney. Spine 1990;15:708-712) and CC (Goodwin et al. Spine 1999;24:1349-135) can significantly increase the success rate of lumbar fusions. There are also reports of augmentation of peripheral nerve regeneration and function and promotions of angiogenesis (Bassett.
Bioessays 1987;6:36-42). Patients with persistent rotator cuff tendonitis refractory to steroid injection and other conventional measures showed significant benefit compared with placebo treated patients (Binder et al. Lancet 1984:695-698). Finally, Brighton et al, have shown in rats the ability of an appropriate CC electric field to both prevent and reverse vertebral osteoporosis in the lumbar spine (Brighton et al. J Orthop Res 1988;6:676-684; Brighton et al. J Bone Joint
Surg 1989;71:228-236).
[00140] More recently, research in this area has focused on the effects that stimulation has on tissues and cells. For example, it has been conjectured that direct currents do not penetrate cellular membranes and that control is achieved via extracellular matrix differentiation (Grodzinsky Crit Rev Biomed Eng 1983;9:133). In contrast to direct currents, it has been reported that PEMFs can penetrate cell membranes and either stimulate them or directly affect intracellular organelles. An examination of the effect of PEMFs on extracellular matrices and in vivo endochondral ossification found increased synthesis of cartilage molecules and maturation of bone trabeculae (Aaron et al. J Bone Miner Res 1998;4:227-233). More recently, it was reported (Lorich et al. Clin Orthop Related Res 1998;350:246-256) that signal transduction ofa capacitively coupled electric signal is via voltage-gated calcium channels, leading to an increase in cytosolic calcium with a subsequent increase in activated (cytoskeletal) calmodulin.
[0011] Much research has been performed using tissue culture techniques in order to understand the mechanisms of response. In one study, it was found that electric fields increased [*H]thymidine incorporation into the DNA of chondrocytes, supporting the notion that Na’ and
Ca'? fluxes generated by electrical stimulation trigger DNA. synthesis (Rodan et al. Science 1978;199:690-692). Studies have found changes in the second messenger, cAMP, and cytoskeletal rearrangements due to electrical perturbations (Ryaby et al. Trans BRAGS 1986;6;
Jones et al. Trans. BRAGS 6:51, 1986; Brighton and Townsend J Orthop Res 1988;6:552-558).
Other studies have found effects on glycosaminoglycan, sulfation, hyaluronic acid, lysozyme activity and polypeptide sequences (Norton et al. J Orthop Res 1988;6:685-689; Goodman et al. Proc Natl Acad Sci 1988;85:3928-3932).
[6012] It ‘was reportéd in"1996 by one of the present inventors that a cyclic, biaxial 0.17% mechanical strain produces a significant increase in TGF-B1 mRNA in cultured MC3T3-
El bone cells (Zhuang et al. Biochem Biophys Res Commun 1996;229:449-453). Several significant studies followed in 1997. In one study it was reported that the same cyclic, biaxial 0.17% mechanical strain produced a significant increase in PDGF-A mRNA in similar bone cells (Wang et al. Biochem Mol Biol Int 1997:43:339-346). It was also reported that a 60 kHz capacitively coupled electric field of 20 mV/cm produced a significant increase in TGF- mRNA in similar bone cells (Zhuang et al. Biochem Biophys Res Commun 1997;237:225-229).
However, the effect such a field would have on other genes has not been reported in the literature.
[0013] In the above-referenced parent patent application, entitled “Regulation of Genes
Via Application of Specific and Selective Electrical and Electromagnetic Signals,” methods were disclosed for determining the specific and selective electrical and electromagnetic signals for use in creating specific and selective fields for regulating target genes of diseased or injured tissues.
The present invention builds upon the technique described therein by describing the method of determining the voltage and current output required, and the corresponding apparatus for delivering specific and selective electrical and electromagnetic signals to the human hip joinis in patients afflicted with osteoarthritis and other cartilage defects, diseases and injuries.
[0014] The present invention related to treating osteoarthritis and other cartilage diseases, defects, and injuries in human hip joints via the application of specific and selective fields generated by specific and selective electric and/or electromagnetic signals. The invention includes a method of determining the voltage and current of the signal to apply to electrodes or to a solenoid or to at least one coil applied to the hip for treatment.
[0015] More particularly, the invention relates to a method of treating diseased tissue in a human through the application of a specific and selective electric or electromagnetic field to diseased tissue in a buman, including osteoarthritis and other cartilage diseases, defects and injuries in the hip, or used as an adjunct with other therapies (cell transplantation, tissue- engineered scaffolds, growth factors, etc.) in treating cartilage defects in the human hip. The method includes the steps of determining the voltage and current output that produces the desired mV/cm electric field in the articular cartilage of the human hip joint, and other voltage and current values for other effective electric field amplitudes thought or known to be effective. The method includes constructing an anatomic model of the human hip joint and translating the anatomic model to an analytical model of the hip in which the dimensions for the tissues encountered from skin (anterior) firéugh tat and skin (posterior) are determined. Planar circuits were then constructed in which the various tissue conductivities, impedances and current flow were used in calculating the voltage and current required to be applied to surface electrodes placed anteriorly and posteriorly on the skin covering the hip in order to produce an electric field at 20 mV/cm in articular cartilage of the hip joint at a frequency of 60 kHz. One knowledgeable in the field could perform the same analysis at other frequencies, adjust the tissue impedances to their values at the new frequency and obtain different values for the ranges of the electrical field znd current density at any chosen frequency or set of frequencies.
[0016] The invention also includes a method and a device for treating diseased tissue (such as osteoarthritis), defective or injured tissue in a human hip joint through the application of a specific and selective electric or electromagnetic field to the afflicted tissue in the human hip joint. Such a device in accordance with a capacitive coupling embodiment of the invention includes at least two electrodes adapted for application in the proximity of a patient’s hip joint and a signal generator that generates electric signals for application to the electrodes so as to produce an electric field of amplitude of 20 mV/cm + 15% and a current density of 120 pA/em® + 15% within the synovium and articular cartilage of the patient’s hip joint. An inductive coupling embodiment of the invention includes a coil(s) or solenoid adapted and configured to receive the electric signals to produce these electric fields. Preferably, the signal generator provides one of a plurality of output electric signals with a voltage selected by a user in accordance with a size of the human hip joint. Larger hip joints receive signals of larger voltages. j0617] These and other aspects of the present invention will be elucidated in the following detailed description of the invention.
[0018] The present invention will be apparent from the following detailed description of the invention in conjunction with the accompanying drawings, of which:
[0019] Figure 1 illustrates an anatomic model of the human hip joint showing all the important tissues and structures through which the current passes between the anterior and posterior surface electrodes placed on skin.
[0020] Figure 2 illustrates an analytical model of the human hip joint from which size parameters are determined for each of the tissues and structures indicated. {0021} Figure 3A illustrates a plapar circuit model of the human hip joint showing circumferential flow of current through the fat layers (Is) plus leakage flow of current through the muscle and other soft tissue (Ls), plus current flow across the hip joint (I>) and the impedance (Z) compartments.
[0022] “Figiire” 3B illustiafeda planar circuit showing in detail the current flow and impedances across the hip joint (Zr1)- 10023] Figure 4 illustrates schematically the three currents that were calculated in determining the output current and voltage required to produce a 20 mV/cm field in the articular cartilage of the hip joint. The three currents are the circumferential current, the leakage current, and the current flowing through the hip joint.
[0024] Figure § illustrates electrode placement on the skin that is required to produce the desired electric field in the hip joint.
10025] The invention will be described with reference to Figures 1-5 and Tables 1-3.
Those skilled in the art will appreciate that the description given herein with respect to these figures is for exemplary purposes only and is not intended in any way to limit the scope of the invention. All questions regarding the scope of the invention may be resolved by referring to the appended claims.
[0026] As used herein, the term “signal” is used to refer to a variety of signals including mechanical signals, ultrasound signals, electromagnetic signals, and electric signals outputted by a device. 10027] As used herein, the term “field” refers to an electric field within a targeted tissue, whether it is a combined field or a pulsed electromagnetic field, or generated by direct current, capacitive coupling, or inductive coupling.
Determination of Voltage and Current:
[0028] Previous studies by the present inventors have shown that a capacitively coupled field significantly increased the proliferation of bone cells grown in culture (Brighton, Pollack, et al, V. Orthop. Research, 3:331-340, 1985) and significantly increased the rate of healing in a rat fractured fibula model (Brighton, Pollack, et al, Clin. Orthop. And Related Research, 285:255- 262, 1992). Also, the field distributions in the vertebral bodies of rats during capacitively coupled electrical stimulation have been determined (Carter, Vresilovic, Pollack, and Brighton,
IEEE transactions on Biomedical Engineering, 36(-3): 333-3345,1989). In order to determine the required output voltage and current required to produce an equivalent electric field and current density in a human hip joint, the analytical model depicted in Figure 2 was developed in accordance with the invention for representing the typical human hip joint illustrated in Figure 1.
fo02y) As shown 1n rigure 1, we typical human hip joint includes layers of cartilage and synovial fluid that is bounded by the acetabulum and the femoral head. In accordance with the invention, osteoarthritis, cartilage disease, defects and injuries in the hip joint is treated by the application of specific and selective electric fields via electrodes 10, 20 attached relative to the hip joint substantially as shown in Figure 1. A signal generator 30 provides the appropriate signals to the electrodes for generating the specific and selective electric fields. The specific and selective electric field needed to treat osteoarthritis, cartilage disease, defects and injuries in the hip joint is calculated in accordance with the invention using the analytical model of the hip joint depicted in Figure 2. ’
[0030] Figure 1 illustrates an anatomical model for use in determining the electric field amplitude and current density obtained in the cartilage space in a hip joint when electrodes 10, are placed anteriorly and posteriorly, respectively, and a voltage is applied causing a current to flow through the body. In the analytical model of Figure 2, the following elements are identified as indicated: electrodes 10, 20, skin 40, fat 50, muscle 60, bone (acetabulum) 70, cartilage and synovial fluid 80, and femoral head 90. In an exemplary embodiment, the frequency of a sine wave voltage is taken to be 60 kHz; however, the methodology described herein can be applied to any frequency as long as the electrical properties of the tissues are chosen for those frequencies. It is desired to determine the voltage and the current to be applied to the electrodes 10, 20 in order to obtain in the cartilage of the hip joint a therapeutic electric field amplitude of 20 mV/cm in a preferred embodiment, and voltage and current values for other effective electric field amplitudes known to be effective.
[0031] It is clear from Figures 1 and 2 that patients of different sizes may require different applied voltages and currents to achieve the therapeutic electric field amplitudes.
Accordingly, the calculation in accordance with the invention will model the patient for four (4) different size classifications. The essential geometric model parameters for these four sizes along with the relevant electrical properties of all tissue types are shown below in Tables 1A and 1B with reference to the distances illustrated in Figure 2. The electrodes 10, 20 are assumed to be 2" x 2" square and the currents are calculated by considering the current flow through the patient’s body for a 2" x 2" rectangle from one electrode to the other plus the circumferential flow of current through the fat layer plus the leakage current that flows through the muscle and other soft tissues outside of the 2" x 2" rectangle but excluding the circumferential current in the fat layer.
These currents are shown in Figures 3 and 4. The impedances of the tissue compartments through which the current I (Figure 3) flows are shown in Figure 3B. A line drawing showing patient electrode placement is presented in Figure S. In Figure 5, the region in broken lines is modeled as a 2” x 2” rectangle 100 in which the body current is assumed to flow. Leakage currents as shown in Figures 3A and 4 include circumferential flow in the fat layer and body currents outside of the 2” x 2” rectangle 100. The current flow and impedance through region 100 are those shown in Figure 3B.
TABLE 1A. Size Parameters for Four Patient Classifications
Patient Classification
Measurement Large | Extra-Large
Flectrode-to electrode distance (D* 0.1524 0.21 [0.305
Fat layer thickness (F* 0.00635 | 0.00762 | 0.0222 10.699 _]
Fat layer width 0.051 0.051 0.051 0.051
Muscle (M3*) length 0051 10.0635 |0.0635 | 0.0635
Muscle (M;*) width 0.051 [0.051 0051 [0.051
Muscle (M,*) length 0.0635 10.0762 [0.0762 | 0.0762
Muscle (M4*) width 0.0254 [0.0254 |0.0254 [0.0254
Muscle (Ms*) length 0.0254 |0.0254 [0.0254 | 0.0254
Muscle (Ms*) width 0.051 0.051 0.051 0.051
Cartilage junction length
Cartilage junction width 0.0127 10.0127 [0.0127 |0.0127
Femoral head radius (R* 0.0254 |0.0254 |0.0254 | 0.0254
Acetabular thickness (B* 0.015 [0.015 0.015 0.015
Acetabular width 0.04 *Sec Figure 2
TABLE 1B. Electrical Conductivities
TISSUE | CONDUCTIVITY
Bone 0.01 S/m
Cartilage — 06Sm
Skin Admittance 3 x 10° S/em’
[0032] The definitions of terms in Figures 2, 3A, 3B and 4 are shown below in Table 2.
Each impedance labeled in Figures 3 and 4 was calculated using the relationship: z= Lo Lens (Equation 1) o Area
Where Length is the dimension of the tissue in the direction of the current flow, Area is the cross-sectional area of the tissue perpendicular to the direction of current flow, and o is the electrical conductivity.
TABLE 2. Definitions of dimensions and symbols shown in Figures 2 and 3 ee ——
D = electrode to electrode distance dh thndatintth anh
F = fat layer thickness
M = muscle:
M, = distance (thickness) of muscle from posterior fat layer to posterior acetabulum
M, = distance (thickness) of muscle from posterior acetabulum to anterior acetabulum
M; = distance (thickness) of muscle from anterior acetabulum to anterior fat layer
Z = impedance: 7, = impedance of skin
Z, = impedance of fat
Z, = impedance of muscle posterior to the acetabulum 7, = impedance of the muscle around the hip joint
Zs = impedance of bone (acetabulum)
Zmd Zg= impedance of bone (femoral head) 7, = impedance of articular cartilage-synovium 7 = impedance of muscle anterior to the acetabulum
Zr, =impedance across the hip joint; i.e., the combined impedance from Point A to Point B in Figure 3B : 1 = : 1
I = current:
Iota = total current flowing from electrode to electrode
Igy = current flowing through hip joint
I, = current flowing through muscle
I = current flowing through femoral head
I, = current flowing throu articular cartilage
B = Bone (acetabulum) thickness
L—
C = cartilage-synovium thickness
R = radius of femoral head —
J = current ee
E = electric field (V/cm)
[0833] The impedances were then calculated using Equation 1, the dimensions in Table 1A and the conductivities in Table 1B. Using standard lump circuit analysis for series/parallel impedances, the total current, I (Figure 3A) that must flow from the electrodes was calculated for each patient classification for a voltage applied to the electrodes. In addition, I, the current flow through the muscle-femur-cartilage-muscle layers; the current L;, the current flowing circumferentially through the fat layer and Ly, the leakage currents, were also calculated. This enabled the calculation of the current through the cartilage, Leanitage and the current density,
Jeartitages from which the electric field amplitude in the cartilage, Ecartitage, could be computed from the equation:
Jeartilage = Ocartilage © Ecartilage (Equation 2) where Jeartitage ADA Ecartilage aT€ described above and Geartilege iS the electrical conductivity of the cartilage as shown in Table 1B. These results are summarized in Table 3A. From Table 3A, itis apparent that for an applied voltage of approximately 5 V peak-to-peak sine wave at 60 kHz, one obtains electric fields of 20 mV/em + 3.5 mV/em for the small, medium and large patient, but not for the extra-large patient. The extra-large patient requires a voltage that is approximately twice that required for the other three patient sizes.
TABLE 3A. Device Voltage and Current Required to Apply 20 mV/cm Electric Field to
Cartilage in the Human Hip
Eer= cp lo lovxavclcrodg | Density
Small 4.3 Vp
ET — SE 1.23 mA/om [Tage | . TT 320mA | 124mAfom’
Extra Large 10.2 Vpp 52.1 mA 2.02 mA/cm
[0034] Tt is now possible to calculate the device current to the 2" x 2" electrodes 10, 20 in order to achieve a 20 mV/cm electric field amplitude in the cartilage. These values, and the approximate device voltages that achieve these device currents are shown below in Table 3B along with the current and current density in the cartilage when the applied voltage is as shown for each patient size:
TABLE 3B. Cartilage Current and Current Density When a 20 mV/cm Electric Field is
Applied to the Cartilage of the Human Hip
IS SY S— TS 120 ple?
Extra Large 0.15 mA 127 pAlem® 10035] 1t is noted that for extra-large patients, the current density value at the electrodes, 2.02 mA/cm?, is at the maximum value and should not be exceeded.
[0036] It is understood that patients with a specific size, ie. electrode-to-electrode dimension, may have tissue compartment sizes and/or skin impedance values that differ from those modeled here. Therefore, devices that power the electrodes should have output variability to increase the peak-to-peak voltage to achieve the desired electrode current (density).
[0037] The current (or electric field) that flows through the cartilage of the hip when a voltage is applied to the electrodes on the skin is determined by the impedances shown in
Figures 3A and 3B. For 2 given patient size, the dimensions of various tissue compartments (and therefore their impedances) can vary sO that the current that actually flows through the cartilage could be higher or lower than the values shown for an applied device voltage as shown above. Taking reasonable variations in dimensions of the tissue compartments for each patient size, it may be determined that for a given device voltage, the cartilage current (and therefore the cartilage electric field) could differ by 15%. Therefore, in order to account for this variation, and to account for the variation of skin electrical impedance from patient to patient, the device should be designed to apply the device current value plus or minus 15% to the pair of 2" x 2" electrodes 10, 20.
[0038] Thus, in accordance with the invention, the approximate size of the patient’s hip is determined, and a signal is generated and applied to the electrodes that will generate the desired electric field with a voltage of 20 mV/cm£15% and a current density of 120 pA/em’+15% within the synovium and articular cartilage for treatment of osteoarthritis in the hip, for example. Preferably, the signal generator includes a select control (Figure 1) that allows the operator to select the proper output based on the size of the patient’s hip. [0039} Although implementations of the invention have been described in detail above, those skilled in the art will readily appreciate that many additional modifications are possible without materially departing from the novel teachings and advantages of the invention. For example, those skilled in the art will appreciate that the techniques of the invention may be applied to capacitive and inductive coupling systems. In the case of capacitive coupling, the scaled Voltags” afd -cufent dre afpired to the hip region using two electrodes as illustrated in
Figures 1 and 2. On the other hand, in the case of inductive coupling, the scaled voltage and current are applied to the hip region using a solenoid or coil(s). Any such modifications are intended to be included within the scope of the invention as defined in the following claims.
Claims (8)
1. A device for treating diseased tissue in the human hip joint through the application of a specific and selective electric or electromagnetic field to the diseased or injured tissue in the human hip joint comprising:
a. one of (a) at least two electrodes, in the case of capacitive coupling, adapted for application in the proximity of a patient’s hip joint; and (b) a solenoid or at least one coil, in the case of inductive coupling, adapted for application in the proximity of a patient's hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm + 15% and a current density range of approximately 120 pA/cm? + 15% within the synovium and articular cartilage of the patient’s hip joint.
2. A device for treating osteoarthritis, cartilage defects due to trauma or sports injury, or used as an adjunct with other therapies for treating cartilage defects in a human hip joint through the application of specific and selective electric or electromagnetic field to the afflicted tissue in the human hip joint, comprising:
a. one of (a) at least two electrodes on the surface of the skin and (b) a solenoid or at least one coil located external to the skin adapted for application in the proximity of a patient’s hip joint; and b. a signal generator that generates electric signals for application to the electrodes, the solenoid, or at least one coil so as to produce an electric field of approximately 20 mV/cm + 15% and a current density range of approximately 120 pA/cm? + 15% within the synovium and articular cartilage of the patient’s hip joint. -14- AMENDED SHEET
PCT/US2004/037926
3. A device as in claim 2, wherein the signal generator provides one of the plurality of output electric signals in accordance with a size of the human hip joint and its surrounding soft tissue and skin.
4. A device as in claim 3, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 4.3 V, + 10% for a small size hip joint.
5. A device as in claim 3, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 4.5 V + 10% for a medium size hip joint.
6. A device as in claim 3, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 5.7 V,, + 10% for a large sized hip joint.
7. A device as in claim 3, wherein one of the plurality of output electrical signals of the signal generator for a 60 kHz frequency has a voltage of approximately 10.2 V, + 10% for an extra large sized hip joint.
8. A device of any one of claims 1 to 7, substantially as herein described with reference to and as illustrated in any of the drawings. -15- AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52008803P | 2003-11-14 | 2003-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200604880B true ZA200604880B (en) | 2007-11-28 |
Family
ID=40666880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200604880A ZA200604880B (en) | 2003-11-14 | 2006-06-13 | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200604880B (en) |
-
2006
- 2006-06-13 ZA ZA200604880A patent/ZA200604880B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7215995B2 (en) | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip | |
US7468264B2 (en) | Method and device for treating osteoarthritis, cartilage disease, defects and injuries in the human knee | |
US6919205B2 (en) | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals | |
USRE41391E1 (en) | Regulation of type II collagen gene expression using specific and selective electrical and electromagnetic signals | |
US7374916B2 (en) | Regulation of aggrecan gene expression using specific and selective electrical and electromagnetic signals | |
US20040138709A1 (en) | Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals | |
ZA200604880B (en) | Method and device for treating osteoarthritis and cartilage disease, defects, and injuries in the human hip |